Name: UMIN ID:
Unique ID issued by UMIN | UMIN000012491 |
---|---|
Receipt number | R000014619 |
Scientific Title | Phase II study of a utility and the biomarker of the capecitabine plus cisplatin chemotherapy for the HER2-negative gastric cancer which is impossible of curative resection |
Date of disclosure of the study information | 2013/12/05 |
Last modified on | 2021/08/14 16:44:18 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/12/04 17:56:15 | ||
2 | Update | 2014/04/06 15:08:53 | Acronym Acronym |
|
3 | Update | 2014/06/06 18:25:19 | UMIN ID1 |
|
4 | Update | 2014/06/07 10:28:22 | Key secondary outcomes Key secondary outcomes |
|
5 | Update | 2019/12/13 15:19:15 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of primary person or sponsor Organization Organization Organization Address Address Tel Institutions |
|
6 | Update | 2021/08/14 16:44:18 | Recruitment status Date of IRB |